GILT Docetaxel - Non-Small Cell Lung Cancer

• Status: Completed
• Trial end date: 1969-12-31

Summary

Primary Objective:

• To compare response rate between genotypic groups and control group.

Secondary Objective:

• To determine the safety, time to treatment failure and survival in control and genotypic arms.

• Phase: Phase 3

Details

• Lead Sponsor: Sanofi
• Treatments: Docetaxel; Gemcitabine